نتایج جستجو برای: her2 amplification

تعداد نتایج: 71537  

Journal: :Journal of clinical pathology 2005
H Awaya Y Takeshima O Furonaka N Kohno K Inai

AIMS To investigate the importance of gene amplification and EGFR (epidermal growth factor receptor) and HER2 protein expression during the progression of adenocarcinoma of the lung. METHODS EGFR and HER2 gene amplification was examined in atypical adenomatous hyperplasia (AAH), bronchioloalveolar carcinoma (BAC), and adenocarcinoma with mixed subtypes (MX) by chromogenic in situ hybridisatio...

2016
Michael F. Press Catherine E. Ellis Robert C. Gagnon Tobias J. Grob Marc Buyse Ivonne Villalobos Zhiyong Liang Shafei Wu Yung-Jue Bang Shu-Kui Qin Hyun Cheol Chung Jianming Xu Joon Oh Park Krzysztof Jeziorski Karen Afenjar Yanling Ma Monica C. Estrada Douglas M. Robinson Stefan J. Scherer Dennis J. Slamon

HER2/ERBB2 status is used to select patients for HER2-targeted therapy.HER2/ERBB2 amplification/overexpression of upper gastrointestinal (UGI) adenocarcinomas was determined locally or in two central laboratories to select patients for the TRIO-013/ LOGiC trial of chemotherapy with or without lapatinib. Patients selected locally had central laboratory confirmation of HER2 amplification for incl...

Journal: :Molecular cancer therapeutics 2017
Michael F Press Catherine E Ellis Robert C Gagnon Tobias J Grob Marc Buyse Ivonne Villalobos Zhiyong Liang Shafei Wu Yung-Jue Bang Shu-Kui Qin Hyun Cheol Chung Jianming Xu Joon Oh Park Krzysztof Jeziorski Karen Afenjar Yanling Ma Monica C Estrada Douglas M Robinson Stefan J Scherer Guido Sauter J Randolph Hecht Dennis J Slamon

HER2/ERBB2 status is used to select patients for HER2-targeted therapy. HER2/ERBB2 amplification/overexpression of upper gastrointestinal (UGI) adenocarcinomas was determined locally or in two central laboratories to select patients for the TRIO-013/LOGiC trial of chemotherapy with or without lapatinib. Patients selected locally had central laboratory confirmation of HER2 amplification for incl...

2013
JUN-XING HUANG KUN ZHAO MEI LIN QI WANG WEI XIAO MAO-SONG LIN HONG YU PING CHEN RONG-YU QIAN

The aim of the present study was to detect the amplification of the human epidermal growth factor receptor 2 (HER2) gene in esophageal squamous cell carcinoma (ESCC), gastroesophageal junction adenocarcinoma (GEJAC) and gastric cancer (GC), as well as to understand the pathological meaning of HER2 gene amplification with regard to clinico-pathological parameters in these types of cancer. HER2 g...

2011
Kyeongmee Park Sehwan Han Jung-Yeon Kim Hyun-Jung Kim Ji Eun Kwon Geumhee Gwak

PURPOSE Valid determination of HER2 status is a prerequisite to establish an adequate treatment strategy for breast cancer patients, regardless of the disease stage. The goal of this study was to examine the feasibility of the newly developed silver-enhanced in situ hybridization (SISH) technique as an alternative to fluorescence in situ hybridization (FISH) for HER2 assay in primary invasive b...

2013
Savitri Krishnamurthy Farideh Bischoff Julie Ann Mayer Karina Wong Tam Pham Henry Kuerer Ashutosh Lodhi Anirban Bhattacharyya Carolyn Hall Anthony Lucci

Human epidermal growth factor receptor 2 (HER2) gene amplification in circulating tumor cells (CTCs) and disseminated tumor cells (DTCs) might be useful for modifying Herceptin therapy in breast cancer. In the process of investigating the utility of a microfluidic platform for detecting HER2 gene amplification in these cells, we observed novel results on discordance of HER2 status. Peripheral b...

Journal: :Journal of clinical pathology 2015
Laura J Tafe Heather B Steinmetz Samantha F Allen Betty J Dokus Gregory J Tsongalis

Evaluation of HER2 (ERBB2) gene amplification or protein expression is standard of care in breast (BR) and advanced stage gastro-oesophageal cancers to identify patients eligible for anti-HER2 therapies. Here, we evaluate a rapid fluorescence in situ hybridisation (FISH) technology (HER2 instant quality (IQ) FISH pharmDx Kit) for detection of HER2 in patients with BR and gastro-oesophageal canc...

2006
Izabela Brożek Iwona Kardaś Karolina Ochman Jarosław Dębniak Maciej Stukan Magdalena Ratajska Lucyna Morzuch Janusz Emerich Janusz Limon

Whereas HER2 amplification is a well-known phenomenon in breast tumours, its frequency and clinical importance in ovarian cancer have not been established. The aim of the study was to compare the frequency of HER2 amplification in hereditary (BRCA-positive) and sporadic (BRCA-negative) ovarian tumours and to estimate the association of this gene alteration on clinical outcome in ovarian cancer ...

Journal: :Journal of clinical pathology 2012
Sara Bravaccini Claudia Rengucci Laura Medri Wainer Zoli Rosella Silvestrini Dino Amadori

A significant proportion of breast cancers with HER2 amplification show simultaneous amplification or deletion of Topo 2. Amplification of Topo 2 may lead to the overexpression of the Topo 2 protein and ultimately to hypersensitivity to Topo 2 inhibitors. HER2 and Topo 2 gene status in breast cancer patients has been determined in several studies using immunohistochemistry, florescence in situ ...

2015
Sameh Mikhail Kristen Ciombor Anne Noonan Christina Wu Richard Goldberg Weiqiang Zhao Lai Wei Kristina Mathey Melissa Yereb Cynthia Timmers Tanios Bekaii-Saab

INTRODUCTION Targeting HER2 has improved outcomes in metastatic GE (mGE) cancer. In this study, we aim to explore the feasibility of molecular profiling in patients with refractory mGE cancer in routine clinical practice. METHODS Archival formalin-fixed, paraffin-embedded (FFPE) samples for patients with mGE were analyzed with commercially available targeted next generation sequencing (NGS) a...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید